Minimization of inflammation in the treatment of bladder tumors by intravesical instillation of adriamycin.
The purpose of this trial was to minimize local inflammation caused by intravesical instillation of antitumor agents, especially Adriamycin, in the treatment of bladder tumor. Tranexamic acid was chosen as the solvent vehicle for Adriamycin and IV bolus injection of an antiallergic drug, Stronger neo-minophagen C, was given at the time of each instillation. Of 81 cases scheduled for Adriamycin instillation therapy, nine cases (11.1%) dropped out due to severe bladder inflammation, while 17 other cases (21%) experienced local side-effects which were tolerated. Of 62 evaluable cases in whom more than eight instillations were performed, complete regression was observed in six cases (9.7%) and partial regression in 20 cases (32.3%).
D000818:Animals; D003556:Cystitis / Q000139:chemically induced / Q000517:prevention & control*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D014677:Pharmaceutical Vehicles; D010976:Platelet Count; D051381:Rats; D011919:Rats, Inbred Strains; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
D014677:Pharmaceutical Vehicles; D004317:Doxorubicin